ARCUS BIOSCIENCES INC (RCUS) Stock News

Arcus Biosciences Shares Are Down Today: What's Going On?

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock offering.

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

/PRNewswire/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among...

Mentions: ONCY AKYA CKPT BCTX

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Arcus Biosciences Announces New Employment Inducement Grants

First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma